Navigation Links
YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
Date:6/23/2009

MISSISSAUGA, ON, June 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that its licensee for nimotuzumab, Daiichi-Sankyo Co., Ltd. in Japan advises that it has commenced enrollment of a Phase II trial evaluating nimotuzumab in combination with radiation therapy/cisplatin/vinorelbine in first-line curative intent patients with Stage III non-small-cell lung cancer (NSCLC). The trial will evaluate the treatment completion rate and numerous secondary endpoints including response rate, progression-free survival, and the overall survival rate at 12 and 18 months as well as toxicity.

"This is the latest of eleven Phase II and III trials currently being conducted by YM and/or its four licensees, highlighting the tremendous breadth of clinical activity focused on nimotuzumab and the benefits of our cooperative model which permits the undertaking of such a comprehensive international program," said David Allan, Chairman and CEO of YM BioSciences. "Of these trials, three involve patients with NSCLC at various stages - curative, palliative radiotherapy and metastatic. NSCLC is an important indication for nimotuzumab as treatments typically involve radiation-containing regimens that have been demonstrated to enhance the expression of EGFR. Nimotuzumab's differentiated mechanistic attributes result in it selectively targeting tissues over-expressing EGFR while avoiding normal tissue. The debilitating and dangerous side effects observed with the marketed EGFR-targeted drugs result from their indiscriminant targeting of normal healthy tissues in addition to their binding to tumor."

YM and its licensee Kuhnil Pharmaceutical Co. in Korea recently collaborated
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... DUBLIN , September 19, 2014 ... Research and Markets ( http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the ... Pre-packed Chromatography Columns"  report to their offering.  ... columns market is one of the fastest-growing segments ... at $1.2 billion in 2013, and expected to ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 Bipartisan passage ... a bill designed to stimulate development and commercialization of ... being praised by leaders of SPIE, the international ... Revitalizing American Manufacturing and Innovation (RAMI) Act, now moves ... authors have said they are optimistic that it will ...
(Date:9/18/2014)... 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research ... and "2014 Deep Research Report on Global and ... database. Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... Global and China Acetic Acid Industry" is a ... China and Global Acetic Acid Market. ...
(Date:9/18/2014)... 18, 2014 ... ) has announced the addition of ... Strategic Business Report" report to ... report analyzes the worldwide markets for ... the following Product Segments: Polymeric Materials, ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 2House passage of high-tech manufacturing bill is move toward stronger economy, say SPIE leaders 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... At the Boston Atrial,Fibrillation Symposium, Stereotaxis, Inc. (Nasdaq: ... remote magnetic ablation that it believes will enhance ... Navigation,System. In booth #917, Stereotaxis will exhibit ... Cardiodrive(R) System for enhanced remote,catheter control and improved ...
... 14 In meetings held in association,with the JP ... (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and ... approvals in 2009 in,addition to potential label expansion for ... Spectrum Pharmaceuticals, Inc.,(Spectrum) for Zevalin. , ...
... At the end of December,Trinitas Comprehensive Cancer Center ... state of New Jersey to offer cancer patients treatment ... VAR ).,RapidArc is a fast, precise form of ... is possible with conventional radiation therapy,technologies. By delivering ...
Cached Biology Technology:Stereotaxis Showcases Advancements for Remote Magnetic Ablations 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 3Stereotaxis Showcases Advancements for Remote Magnetic Ablations 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 2Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 5Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 6Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 2Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 3
(Date:9/18/2014)... novel robotic system that can operate inside the bore ... part of a biomedical research partnership program at Brigham ... determining if the robot, in conjunction with real-time MRI ... less costly, and less discomforting for the patient. The ... cancer therapies with greater precision. , Developed by a ...
(Date:9/18/2014)... acquire and creatively manipulate spoken language is unique to ... 6 million years of human evolution to make this ... candidate gene we now have," says Wolfgang Enard, Professor ... efforts to understand the molecular biological basis of language ... results of his latest study, undertaken in collaboration with ...
(Date:9/18/2014)... generally seem to be cheerful, happy-go-lucky characters, so you ... on life. , In fact some dogs are ... of Sydney shows. , "This research is exciting ... dogs objectively and non-invasively. It offers researchers and dog ... how that changes," said Dr Melissa Starling, from the ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3
... fossil fuel air pollution in the United States by ... , This novel way to measure carbon dioxide produced ... atmospheric scientists better understand where pollution is located and ... fossil-fuel-emitted carbon dioxide will be important as countries throughout ...
... used to help steady buildings against earthquakes, according to ... loose, sandy soil into rock. , When a major ... with disastrous consequences for buildings sitting on them. Currently, ... bind loose grains together. But these epoxy chemicals may ...
... Friedreich's ataxia is one of those diseases few have heard ... individual -- usually a child or teenager -- it is ... arms and legs, vision impairment and slurred speech, but eventually ... to heart failure later in life. There is no cure ...
Cached Biology News:Scientists map air pollution using corn grown in US fields 2Moonlighting enzyme linked to neurodegenerative disease 2Moonlighting enzyme linked to neurodegenerative disease 3
... The SPD101B is a no-frills, basic SpeedVac ... Although economically priced, this unit still features ... a digitial display of time and heat. ... samples and accepts a wide variety of ...
... Jouan RC Maxi MB (for aqueous, other ... concentrator/centrifugal evaporator systems respond to specific applications ... and safe concentration of heat-labile samples. The ... different of cold traps and a wide ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
...
Biology Products: